Selinexor in Maintenance Therapy After Systemic Therapy for Patients with p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma: XPORT-042

Video Transcription

Video Summary

Dr. Rob Coleman and Flora Backus discussed the advancements in treating recurrent endometrial cancer with a focus on the mismatch repair proficient population. They explored the potential of maintenance treatment options beyond immunotherapy for this group. Dr. Coleman shared insights from ongoing clinical trials, highlighting the significance of biomarkers like P53 mutation status in guiding treatment decisions. They discussed the importance of comprehensive tumor testing using techniques like immunohistochemistry and next-generation sequencing. The conversation also delved into the side effects and patient selection criteria for trials like Export EC. The aim is to provide personalized treatments to improve outcomes for endometrial cancer patients. The session emphasized the need for strategic approaches to optimize treatment efficacy while managing adverse events.

Keywords

endometrial cancer

recurrent

mismatch repair proficient

maintenance treatment

biomarkers

clinical trials